Clinical trial
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With…
NCT03474107 · Astellas Pharma Global Development, Inc., Industry · Completed
Key facts
| NCT number | NCT03474107 |
|---|---|
| Title | A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) |
| Official title | An Open-Label, Randomized Phase 3 Study to Evaluate Enfortumab Vedotin vs Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301) |
| Lead sponsor | Astellas Pharma Global Development, Inc., Industry |
| Collaborators | Seagen Inc. Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ureteral Cancer, Urothelial Cancer, Bladder Cancer |
| Intervention type | Drug |
| Interventions | Enfortumab Vedotin, Docetaxel, Vinflunine, Paclitaxel |
| Enrollment | 608 |
| Start date | Jun 27, 2018 |
| Primary completion | Jul 15, 2020 |
| Completion | Nov 27, 2025 |
| First posted | Mar 22, 2018 |
| Last update posted | Jan 9, 2026 |
| Countries | Argentina, Australia, Austria, Belgium, Canada, Denmark, France, Germany, Italy, Japan, Netherlands, Portugal and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: